ID: ALA205759

Max Phase: Preclinical

Molecular Formula: C33H37N3O6

Molecular Weight: 571.67

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)c2ccc3ccccc3c2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1

Standard InChI:  InChI=1S/C33H37N3O6/c1-5-6-16-26(27(37)29(38)34-21(2)22-12-8-7-9-13-22)35-32(41)42-28-31(40)36(20-33(28,3)4)30(39)25-18-17-23-14-10-11-15-24(23)19-25/h7-15,17-19,21,26,28H,5-6,16,20H2,1-4H3,(H,34,38)(H,35,41)/t21-,26+,28-/m1/s1

Standard InChI Key:  MZSQQNLITAUFDD-UADAULAISA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 571.67

Molecular Weight (Monoisotopic): 571.2682

AlogP: 4.95

#Rotatable Bonds: 10

Polar Surface Area: 121.88

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.24

CX Basic pKa:

CX LogP: 5.92

CX LogD: 5.92

Aromatic Rings: 3

Heavy Atoms: 42

QED Weighted: 0.26

Np Likeness Score: -0.26

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature